Abstract
Background
Iodine 123-labeled metaiodobenzylguanidine (123I-MIBG) can be used to generate a scintigraphic image of the adrenergic nervous innervation of the heart.
Methods and Results
To test the hypothesis that doxorubicin may lead to damage of cardiac neurons, we examined 37 patients with various malignant neoplasms, 14 of whom were on therapy with doxorubicin. All patients were examined with 123I-MIBG scintigraphy and radionuclide ventriculography. Cardiac 123I-MIBG uptake was assessed by means of a heart to mediastinum activity ratio (H/M). Left ventricular ejection fraction was not different in patients with or without doxorubicin. In patients receiving doxorubicin, the H/M ratio was significantly lower (1.73±0.25 vs 2.13±0.25, p<0.001) and correlated with doxorubicin cumulative dose (r=−0.51, p<0.001). By using a H/M ratio of 1.73 as a cutoff point, 123I-MIBG uptake was abnormal in none of the 23 patients not receiving and 6 of 14 patients receiving doxorubicin therapy (p<0.001). In 10 patients initially not receiving doxorubicin, 123I-MIBG scintigraphy was repeated after receiving 236±47 mg/m2 of doxorubicin. The H/M became abnormal in 3 of 10 patients, whereas the ejection fraction became abnormal in 2 of 10 patients.
Conclusion
123I-MIBG cardiac uptake decreases in a doxorubicin dose-dependent way, indicating a cardiac adrenergic neurotoxic effect of doxorubicin. This phenomenon appears early and generally before deterioration of the ejection fraction.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Lefrak EA, Pitha J, Rosenheim S, Gottleib JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973;32:302–14.
Strashun A. Adriamycin, congestive cardiomyopathy and metaiodobenzylguanidine. J Nucl Med 1992;33:215–22.
McKillop JH, Bristow MR, Goris ML, Billingham ME, Bockemuehl K. Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity. Am Heart J 1983;106:1048–56.
Lekakis J, Vassilopoulos N, Psichoyiou H, et al. Doxorubicin cardiotoxicity detected by indium 111 myosin-specific imaging. Eur J Nucl Med 1991;18:225–6.
Carrio I, Estorch M, Berna L, et al. Assessment of anthracycline-induced myocardial damage by quantitative indium 111 myosin-specific monoclonal antibody studies. Eur J Nucl Med 1991;18:806–12.
Wakasugi S, Wada A, Hasegawa Y, Nakano S, Shibata N. Detection of abnormal cardiac adrenergic neuron activity in adriamycin-induced cardiomyopathy with iodine-125-metaiodobenzylguanidine. J Nucl Med 1992;33:208–14.
Wakasugi S, Fischman AJ, Babich JW, et al. Metaiodobenzylguanidine: evaluation of its potential as a tracer for monitoring doxorubicin cardiomyopathy. J Nucl Med 1993;34:1282–6.
Kline RC, Swanson DP, Wieland DM et al. Myocardial imaging in man with I-123 meta-iodobenzylguanidine. J Nucl Med 1981;22:129–32.
Merlet P, Valette H, Dubois-Rande JL, et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med 1992;33:471–7.
Doroshow JH. Doxorubicin-induced cardiac toxicity. N Engl J Med 1991;324:843–5.
Solem LE, Henry TR, Wallace KB. Disruption of mitochondrial calcium homeostasis following chronic doxorubicin administration. Toxicol Appl Pharmacol 1994;129:214–22.
Mettler FP, Young DM, Ward JM. Adriamycin-induced cardiotoxicity (cardiomyopathy and congestive heart failure) in rats. Cancer Res 1977;33:2705–10.
Smith B. Damage to the intrinsic cardiac neurones by Rubidomycin (daunorubicin). Br Heart J 1969;31:607–9.
Schofer J, Spielmann R, Schuchert A, Weber K, Schluter M. Iodine-123 metaiodobenzylguanidine scintigraphy: a noninvasive method to demonstrate myocardial adrenergic nervous system disintegrity in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1988;12:1252–8.
Dae MW, De Marco T, Botrinick EH, et al. Scintigraphic assessment of MIBG uptake in globally denervated human and canine hearts: implications for clinical studies. J Nucl Med 1993;34:1282–6.
Estorch M, Carrio I, Berna L, Lopez-Pousa J, Torres G. Myocardial iodine-labeled metaiodobenzylguanidine 123 uptake relates to age. J Nucl Cardiol 1995;2:126–32.
Nakajo M, Shapiro B, Glowniak J, Sisson JC, Beierwaltes WH. Inverse relationship between cardiac accumulation of meta-131-iodobenzylguanidine (I-131 MIBG) and circulating catecholamines in suspected pheochromocytoma. J Nucl Med 1983;24:1127–43.
Nakajima K, Taki J, Tonami N, Hisada K. Decreased 123-J MIBG uptake and increased clearance in various cardiac diseases. Nucl Med Comm 1994;15:317–23.
Buja LM, Ferrans VJ, Mayer RJ, Roberts WC, Henderson ES. Cardiac ultrastructural changes induced by daunorubicin therapy. Cancer 1973;32:771–88.
Jaenke RS. An anthracycline antibiotic-induced cardiomyopathy in rabbits. Lab Invest 1974;30:292–304.
Weinberg LE, Singal PK. Refractory heart failure and agerelated differences in adriamycin-induced myocardial changes in rats. Can J Physiol Pharmacol 1986;65:1957–65.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lekakis, J., Prassopoulos, V., Athanassiadis, P. et al. Doxorubicin-induced cardiac neurotoxicity: Study with iodine 123-labeled metaiodobenzylguanidine scintigraphy. J Nucl Cardiol 3, 37–41 (1996). https://doi.org/10.1016/S1071-3581(96)90022-7
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1016/S1071-3581(96)90022-7